Objective
It has been recognized that growing cells within 3D structures reduces the gap between 2D in vitro cell cultures and native tissue physiology. This has been paving the way for the development of reliable 3D in vitro cell-based platforms with major impact in the reduction/elimination of animal experimentation, diseases modelling and drug development. So far, the many strategies that have been followed to bioengineer in vitro 3D human tissue models mostly rely on the random culture of cells within a 3D structure without reflecting the compositional and structural complexity of the native tissues. Recently proposed bioprinting technologies that allow accurate and high speed deposition of various cells and matrices at high resolution, have therefore great potential in the development of physiologically reliable 3D in vitro tissue models by recreating the different microenvironments/microfunctionalities found in each tissue. Nonetheless, among the components required for bioprinting, bioinks in particular have demanding requirements and much has still to be done regarding their intrinsic formulation to lead cell behaviour and support specific functionalities.
ECM_INK intends to tackle this issue by developing cells-self extracellular matrices-based bioinks to create accurate and pathophysiological relevant 3D in vitro diseased skin tissue models. The development of cell phenotype-driven bioinks will generate complex microenvironments comprising varied cell types within matrices that were specifically designed to attain a particular response from each one of those cell types. The use of cells from patients suffering from chronic, genetic and neoplastic skin diseases represents a major advantage that will be reflected in the accuracy and functionality of the respective 3D in vitro models. The ultimate confirmation of their potential will be complete after validation using animal-free approaches reinforcing the intrinsic relationship of ECM_INK with the 3Rs policy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine physiology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-COG - Consolidator Grant
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2016-COG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4704 553 Braga
Portugal
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.